A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Phase 2 Active not recruiting 40 enrolled Institute of Hematology & Blood Diseases Hospital, China

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRd(Bortezomib, Lenalidomide and Dexamethasone)-based regimen combined with BCMA CAR-T in Chinese transplant-ineligible patients with newly diagnosed multiple myeloma

Timeline

Start: 2023-04-04
Primary completion: 2025-06-01
Completion: 2028-03-10

Publications

Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G. Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). J Clin Oncol. 2026 Apr 10;44(11):992-1002. doi: 10.1200/JCO-25-01969. Epub 2026 Feb 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Subject	Dexamethasone	Small molecule	40 mg	—
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Subject	anti-BCMA CAR-T	Cell therapy	2e+06 cells/kg	Intravenous
Subject	anti-BCMA CAR-T	Cell therapy	4e+06 cells/kg	Intravenous

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications